Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia characterized by temporally and spatially heterogeneous fibroblast proliferation and poor prognosis. No therapies have been shown in randomized clinical trials (RCT) to influence survival. Twenty-nine subjects were assigned randomly in a pilot study to a double-blind, placebo-controlled, RCT to test sildenafil in patients with IPF with forced vital capacity 40-90% and diffusing capacity 30-90% of predicted. During the 6-month experimental treatment period, patients underwent 6-min walk tests and estimation of dyspnea using the Borg scale at baseline (0 months), 3 months, and 6 months. Participants had moderate impairment of pulmonary function, and there were no significant differences between placebo (n = 15) and sildenafil (n = 14)-treated groups. Sildenafil did not significantly increase 6-min walk test distance (mean distance +/- SD after 6-month protocol: placebo 355 +/- 82 m, sildenafil 324 +/- 41 m; p = 0.256) nor did it lessen dyspnea after exercise (mean Borg score after 6-month protocol: placebo 3.4 +/- 1.6, sildenafil 4.1 +/- 2.3; p = 0.492). Adverse reactions were few and minor in nature. In this trial, sildenafil did not significantly increase 6-min walk test distance or decrease the Borg dyspnea index in patients with clinically typical IPF. This trial was registered at clinicaltrials.gov as NCT00359736.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pamrevlumab which is a monoclonal antibody that is directed against connective tissue growth factor appeared to attenuate the progression of IPF.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [69]
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Redelmeier, D. A., Bayoumi, A. M., Goldstein, R. S., & Guyatt, G. H. (1997) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.155.4.9105067 · Cited by 1,029 · cited 2×
“No such change occurred, indicating the absence of a drug effect exceeding this distance; 54 m is sometimes considered a ‘‘clinically important’’ change in 6-MWT distance in patients with chronic obstructive pulmonary disease [10].”
BackgroundEchocardiographic Assessment of Pulmonary Hypertension in Patients with Advanced Lung Disease
Arcasoy, S. M., Christie, J. D., Ferrari, V. A., Sutton, M. S. J., Zisman, D. A., Blumenthal, N. P., Pochettino, A., & Kotloff, R. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1130oc · Cited by 906 · cited 1×
“Echocardiographic estimates of pulmonary pressure may not accurately reflect pressures measured by catheterization in the setting of interstitial lung disease [16].”
BackgroundPrevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Lettieri, C. J., Nathan, S. D., Barnett, S. D., Ahmad, S., & Shorr, A. F. (2006) · Chest · doi:10.1378/chest.129.3.746 · Cited by 879 · cited 1×
“The echocardiographic pressure estimates (Table 4) and NT-pro BNP data cited earlier demonstrate that this cohort was at risk for pulmonary hypertension, consistent with the literature [1, 12, 13].”
ResultSildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769 · cited 2×
“patients with severe pulmonary fibrosis and pulmonary hypertension associated with disorders of the respiratory system (mean pulmonary arterial pressure 42 mmHg) [5].”
BackgroundResultGuidelines for the six-minute walk test
Ats, S. (2002) · Medical Entomology and Zoology · Cited by 651
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Shorr, A. F., Wainright, J. L., Cors, C. S., Lettieri, C. J., & Nathan, S. D. (2007) · European Respiratory Journal · doi:10.1183/09031936.00107206 · Cited by 377
Ghofrani, H. A., Reichenberger, F., Kohstall, M. G., Mrosek, E. H., Seeger, T., Olschewski, H., Seeger, W., & Grimminger, F. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-3-200408030-00005 · Cited by 309 · cited 1×
“However, in contrast to its salutary effects at altitude [15], sildenafil did not increase the exercise capacity of patients with IPF in this trial.”
Background
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
King, C. S., & Nathan, S. D. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30222-3 · Cited by 186
Phosphodiesterase 5 inhibitors for pulmonary hypertension
Barnes, H., Brown, Z., Burns, A., & Williams, T. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012621.pub2 · Cited by 143
A review of current and novel therapies for idiopathic pulmonary fibrosis.
Rafii, R., Juarez, M. M., Albertson, T. E., & Chan, A. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.12.07 · Cited by 173
“There was unfortunately no significant improvement in 6MWD distance or dyspnea score in the sildenafil treatment group (65).”
BackgroundBehr, J., Nathan, S. D., Wuyts, W. A., Mogulkoc Bishop, N., Bouros, D. E., Antoniou, K., Guiot, J., Kramer, M. R., Kirchgaessler, K.-U., Bengus, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30356-8 · Cited by 134
Pulmonary hypertension in chronic interstitial lung diseases
Caminati, A., Cassandro, R., & Harari, S. A. (2013) · European Respiratory Review · doi:10.1183/09059180.00002713 · Cited by 121
Exercise Limitation in IPF Patients: A Randomized Trial of Pulmonary Rehabilitation
Jackson, R. M., Gómez-Marín, O., Ramos, C. F., Sol, C., Cohen, M. I., GAUNAURD, I. A., Cahalin, L. P., & Cardenas, D. D. (2014) · Lung · doi:10.1007/s00408-014-9566-9 · Cited by 113
“Increased pulmonary vascular resistance in IPF appears to be poorly amenable to therapy [6].”
BackgroundSelf-citationGaunaurd, I. A., Gómez-Marín, O. W., Ramos, C. F., Sol, C. M., Cohen, M. I., Cahalin, L. P., Cardenas, D. D., & Jackson, R. M. (2014) · Respiratory Care · doi:10.4187/respcare.03180 · Cited by 99
Self-citationThe Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease
King, C. S., & Shlobin, O. A. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.04.046 · Cited by 107
Bajwah, S., Ross, J. R., Peacock, J. L., Higginson, I. J., Wells, A. U., Patel, A. S., Koffman, J., & Riley, J. L. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202040 · Cited by 108
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016) · BMC Medicine · doi:10.1186/s12916-016-0558-x · Cited by 101
“Jackson 2010 [23] Single Center USA n = 29 Yes – no bronchoscopy required FVC 40–90 % predicted DLCO 30–90 % predicted Sildenafil 6 months Low Sildenafil 0/14 Placebo 0/15 0/14 0/15 Pfizer UK”
BackgroundGroup III Pulmonary Hypertension
Klinger, J. R. (2016) · Cardiology Clinics · doi:10.1016/j.ccl.2016.04.003 · Cited by 99
Dyspnea in Idiopathic Pulmonary Fibrosis: A Systematic Review
Ryerson, C. J., Donesky, D., Pantilat, S. Z., & Collard, H. R. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.04.026 · Cited by 76
German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
Behr, J., Günther, A., Bonella, F., Geissler, K. H., Koschel, D., Kreuter, M., Prasse, A., Schönfeld, N., Sitter, H., Müller–Quernheim, J., et al. (2018) · Pneumologie · doi:10.1055/s-0043-123035 · Cited by 71
“Sildenafil is an orally available phosphodiesterase (PDE)-5 inhibitor which has been tested in two randomized controlled trials with IPF patients [24,25].”
Lung Transplantation for Pulmonary Hypertension
George, M. P., Champion, H. C., & Pilewski, J. M. (2011) · Pulmonary Circulation · doi:10.4103/2045-8932.83455 · Cited by 64
“[39] Studies have shown variable effects of oral vasodilator therapy in the treatment of PAH associated with lung diseases, presumably due to worsening ventilation/ perfusion mismatch.[40-45] This has been somewhat overcome through the use of inhaled prostacyclins, which may have promise in COPD and interstitial lung…”
BackgroundZimmermann, G., von Wulffen, W., Huppmann, P., Meis, T., Ihle, F., Geiseler, J. G., Leuchte, H. H., Tufman, A., Behr, J., & Neurohr, C. (2014) · Respirology · doi:10.1111/resp.12294 · Cited by 54
Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis
Blanco, I., Ribas, J., Xaubet, A., Gómez, F. P., Roca, J., Rodriguez‐Roisin, R., & Barberà, J. A. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01104.2010 · Cited by 54
Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra
Rajagopal, K., Bryant, A. J., Sahay, S., Wareing, N. E., Zhou, Y., Pandit, L. M., & Karmouty‐Quintana, H. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15036 · Cited by 51
Pulmonary Hypertension in Interstitial Lung Disease
Ang, H. L., Schulte, M., Chan, R. K., Tan, H. H., Harrison, A., Ryerson, C. J., & Khor, Y. H. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.04.025 · Cited by 44
Milara, J., Escrivá, J., Ortiz, J. L., Juan, G., Artigues, E., Morcillo, E. J., & Cortijo, J. (2016) · European Respiratory Journal · doi:10.1183/13993003.01259-2015 · Cited by 43
Gille, T., & Laveneziana, P. (2021) · European Respiratory Review · doi:10.1183/16000617.0355-2020 · Cited by 42
Pulmonary Hypertension Idiopathic Pulmonary Fibrosis: A Dastardly Duo
Smith, J. S., Perez, R. L., Gorbett, D., Mueller, J., & Daniels, C. J. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31827871dc · Cited by 43
S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
Behr, J., Günther, A., Bonella, F., Geissler, K. H., Koschel, D., Kreuter, M., Prasse, A., Schönfeld, N., Sitter, H., Müller–Quernheim, J., et al. (2017) · Pneumologie · doi:10.1055/s-0043-106160 · Cited by 37
“In BUILD-1 (Bosentan Use in Interstitial Lung Disease) wurden 158 IPF-Patienten zu entweder Plazebo oder Bosentan randomisiert und für 12 Monate nachverfolgt [24].”
BackgroundPulmonary hypertension due to interstitial lung disease
King, C. S., & Nathan, S. D. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000599 · Cited by 37
Exploring the Multifaceted Potential of Sildenafil in Medicine
Pușcașu, C., Zanfirescu, A., Negreș, S., & Șeremet, O. C. (2023) · Medicina · doi:10.3390/medicina59122190 · Cited by 38
Nathan, S. D., & King, C. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s64907 · Cited by 32
Behr, J., Nathan, S. D., Harari, S. A., Wuyts, W. A., Kirchgaessler, K.-U., Bengus, M., Gilberg, F., & Wells, A. U. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.03.019 · Cited by 32
Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases
Shlobin, O. A., Brown, A. W., & Nathan, S. D. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.08.002 · Cited by 30
Investigational approaches to therapies for idiopathic pulmonary fibrosis
Gomer, R. H., & Lupher, M. L. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.484018 · Cited by 29
“A second small Phase II study by independent investigators was recently reported which did not show a significant difference in exercise tolerance between sildenafil and placebo [51].”
BackgroundProgress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Nathan, S. D. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202212-2342ci · Cited by 31
Shlobin, O. A., Shen, E., Wort, S. J., Piccari, L., Scandurra, J., Hassoun, P. M., Nikkho, S. M., & Nathan, S. D. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12310 · Cited by 26
“63,65,71,74,76,77,79,82,84,89 It is unknown if a combination of sildenafil and inhaled treprostinil provides incremental efficacy.”
BackgroundBehr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J. C., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2023) · Pneumologie · doi:10.1055/a-1983-6796 · Cited by 26
“Die Behandlung der IPF mit Sildenafil wurde initial in zwei prospektiven Studien untersucht, wobei in der größeren der beiden Studien (STEP-IPF-Studie) prospektiv 180 IPF-Patienten mit 3 ×20mg Sildenafil behandelt wurden [97, 98].”
BackgroundPatient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis
Hart, S. P., Trawinska, M., & Rupesinghe, R. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s81144 · Cited by 27
“It has been studied for use in the treatment of IPF in two randomized, controlled trials.(48,49) The larger of the two trials included 180 patients, but only randomized them to sildenafil or placebo for a period of 12 weeks, at which point all patients continued on sildenafil for a further 12 weeks.”
MethodResultCardiopulmonary Exercise Testing in Patients With Interstitial Lung Disease
Molgat‐Seon, Y., Schaeffer, M. R., Ryerson, C. J., & Guenette, J. A. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00832 · Cited by 30
Exercise decreases plasma antioxidant capacity and increases urinary isoprostanes of IPF patients
Jackson, R. M., Ramos, C., Gupta, C., & Gómez-Marín, O. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.07.021 · Cited by 25
Self-citationA narrative review of research advances in hypoxic pulmonary hypertension
Chai, T., Qiu, C., Xian, Z., Lu, Y., Zeng, Y., & Li, J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-259 · Cited by 24
“Despite this, there have been trials that have shown that sildenafil improves not only symptoms but also exercise endurance (82,83).”
BackgroundYogeswaran, A., Hassoun, P. M., Saleh, K., Fünderich, M., Balasubramanian, A., Konswa, Z., Kiely, D. G., Lawrie, A., Thenappan, T., Eichstaedt, C. A., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202412-2371oc · Cited by 23
Pulmonary hypertension secondary to interstitial lung disease
Shlobin, O. A., & Nathan, S. D. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.11 · Cited by 21
Elinoff, J. M., Agarwal, R., Barnett, C. F., Benza, R. L., Cuttica, M. J., Gharib, A. M., Gray, M. P., Hassoun, P. M., Hemnes, A. R., Humbert, M. J. C., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2093pp · Cited by 24
Diagnosis and Pathophysiological Mechanisms of Group 3 Hypoxia-Induced Pulmonary Hypertension
Woo, K. V., Ornitz, D. M., & Singh, G. K. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0718-3 · Cited by 19
Dudala, S. S., Venkateswarulu, T. C., Kancharla, S. C., Kodali, V. P., & Dulla, J. B. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00304-5 · Cited by 19
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
“Bosentan [65,66], macitentan [67], ambrisentan [68] and sildenafil [64,69] all failed to demonstrate improved physiological or symptomatic measures compared to placebo.”
Bajwah, S., Colquitt, J. L., Loveman, E., Bausewein, C., Almond, H., Oluyase, A. O., Dzingina, M., Maddocks, M. M., Higginson, I. J., & Wells, A. U. (2020) · ERJ Open Research · doi:10.1183/23120541.00107-2020 · Cited by 16
“In the review by B AJWAH et al. [4], sildenafil was assessed in four studies (one before-and-after study [24] and two RCTs [22, 23], of which one of the RCTs [22] was followed by an open-label study) and 378 participants: the before-and after study [24] found a significant mean (90% CI) improvement…”
MethodResultInfluentialChan, P., Bax, L., Chen, C., Zhang, N., Huang, S., Soares, H. D., Rosen, G., & Abutarif, M. A. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12227 · Cited by 16
Martínez, J. A. B., Ferreira, J. C., Tanni, S. É., Alves, L. R., Cabral, B. F., de Carvalho, C. R. R., Cezare, T. J., da Costa, C. H., Gazzana, M. B., Jezler, S. F. D. O., et al. (2020) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20190423 · Cited by 17
“Three clinical trials, of which only two were randomized, have evaluated the effects of sildenafil in patients with advanced IPF.(68-70) The primary outcome used was always a change in the 6MWD, which was not achieved in any of the investigations.”
BackgroundSantoleri, F., Auriemma, L., Spacone, A., Marinari, S., Esposito, F., Vita, F. D., Petragnani, G., Fabio, C. D., Fabio, L. D., & Costantini, A. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211008625 · Cited by 14
Sherner, J. H., Collen, J. F., King, C. S., & Nathan, S. D. (2012) · Current Respiratory Care Reports · doi:10.1007/s13665-012-0027-8 · Cited by 12
“2010 [62] RCT, double-blind 29 Sildenafil Negative study: No difference in 6MWT or Borg score”
BackgroundAdvances in the treatment of idiopathic pulmonary fibrosis
Sergew, A., & Brown, K. M. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1102886 · Cited by 12
Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Pitre, T., Khalid, M. F., Cui, S., Zhang, M. C., Husnudinov, R., Mah, J. C., Helmeczi, W., Su, J. S., Banfield, L., Guy, B., et al. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102128 · Cited by 12
Management of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., & Richeldi, L. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.005 · Cited by 13
Lee, J., & Song, J.-U. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e48 · Cited by 10
Behr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2024) · Respiration · doi:10.1159/000540856 · Cited by 13
Wu, X., Li, W., Luo, Z., & Chen, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02861-w · Cited by 9
“In another RCT, there was no significant difference in FVC (% predicted) in IPF patients ( P = 0.79) between Sildenafil and placebo, and there were few SAEs [20].”
BackgroundResultInfluentialKattih, Z., Kim, H. C., Aryal, S., & Nathan, S. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062029 · Cited by 9
“However, two prospective randomized controlled studies of sildenafil did not show a benefit in the 6MWT distance and Borg score [76,77].”
Tseng, S., Stanziola, A. A., Sultan, S., Henry, K. J., Saggar, R., & Saggar, R. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.03.006 · Cited by 8
Heresi, G. A., Dean, B. B., Wu, B., Lee, H., Sketch, M. R., Stafkey-Mailey, D., Morland, K., Classi, P. M., & Spikes, L. A. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03141-3 · Cited by 9
“Likewise, patients with PH-ILD treated with the phos-phodiesterase-5 inhibitor (PDE5i), sildenafil, showed no benefit in 6MWD or perceived exertion, although one study found improved oxygen saturation and patient quality of life [1, 21, 22].”
BackgroundNovelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others
Correale, M., Totaro, A., Lacedonia, D., Montrone, D., Biase, M. D., Barbaro, M. P. F., & Brunetti, N. D. (2014) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152571131100086 · Cited by 8
Hassoun, P. M., & Nathan, S. D. (2016) · European Respiratory Journal · doi:10.1183/13993003.00395-2016 · Cited by 8
Girgis, R. E., & Hoeper, M. M. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.03.004 · Cited by 8
Pulmonary Hypertension in Parenchymal Lung Disease
Tsangaris, I., Tsaknis, G., Anthi, A., & Orfanos, S. E. (2012) · Pulmonary Medicine · doi:10.1155/2012/684781 · Cited by 6
“[24] R.”
Cottin, V., Valenzuela, C., & Humbert, M. J. C. (2023) · European Respiratory Journal · doi:10.1183/13993003.00944-2023 · Cited by 6
Bongiovanni, G., Tonutti, A., Stainer, A., Nigro, M., Kellogg, D. L., Nambiar, A. M., Gramegna, A., Mantero, M., Voza, A., Blasi, F., et al. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-002161 · Cited by 5
“23 24 In both instances, the primary outcome was not achieved, with the first study focusing on the 6MWD, while the second assessing disease progression.”
BackgroundRaghu, G., Rochwerg, B. N., Zhang, Y., García, C. Á., Azuma, A., Behr, J., Brożek, J., Collard, H. R., Cunningham, W. E., Homma, S. A., et al. (2015) · Cited by 9
Hypertension pulmonaire au cours des maladies respiratoires chroniques
Cottin, V. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.07.006 · Cited by 5
Savale, L., Bertoletti, L., & Cottin, V. (2013) · Respiration · doi:10.1159/000348389 · Cited by 4
Therapeutic options for patients with pulmonary hypertension and interstitial lung disease
Swisher, J. W., & Weaver, E. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251335815 · Cited by 3
Pharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Cottin, V., & Valenzuela, C. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006115 · Cited by 3
Khan, S. L., Psoter, K. J., Lin, C. T., Balasubramanian, A., Simpson, C. E., Lammi, M. R., Tuhy, T., Damico, R. L., Kolb, T. M., Hassoun, P. M., et al. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.02.045 · Cited by 2
Xu, J., Liu, X., Liang, X., Cai, X., & Qian, W. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04342-8 · Cited by 2
Secondary pulmonary arterial hypertension: to treat or not to treat?
Tomic, R., & Hertz, M. I. (2018) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000529 · Cited by 2
Singh, P., Thampi, G., Gupta, K., Gangte, N., PATTNAIK, B. R., Agrawal, A., & Kukreti, R. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2543473 · Cited by 3
Novel drug targets in idiopathic pulmonary fibrosis
Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2
“Further, Sildenafil did not significantly increase 6-min walk test distance or decrease the Borg dyspnea index, failing to show benefit for the treatment of IPF patients [11].”
BackgroundTratamiento farmacológico en la fibrosis pulmonar idiopática. Drogas modificadoras de enfermedad
FLORENZANO, M., V, & C, F. R. (2019) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482019000400287 · Cited by 3
Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations
Weatherald, J. C., Montani, D., & Sitbon, O. (2020) · Respiratory medicine · doi:10.1007/978-3-030-43435-9_6 · Cited by 2
Feshchenko, Y. I., Gavrysyuk, V. K., Горовенко, Н. Г., Dziublyk, O., Pertseva, T. O., Ostrovsky, M. M., Basanets, A. V., Bychenko, O. V., Dziublyk, Y. O., Konopkina, L., et al. (2023) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2023-31-1-5-33 · Cited by 4
Interstitial lung disease-associated pulmonary hypertension – what the future holds
Cottin, V., Diesler, R., Turquier, S., & Valenzuela, C. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000992 · Cited by 2
“Copyright © 2023 Wolters Kluwer H and several randomized control trials in patients with IPF using PAH-approved medications [55– 57], or in patients with IPF or idiopathic interstitial pneumonia and a high risk of pulmonary hypertension based on echocardiography [58] or severely altered DLco [59,60,61 & ].”
Idiopathic Pulmonary Fibrosis: Stem Cell-Mediated Therapeutic Approach
Totey, S. M. (2017) · Springer eBooks · doi:10.1007/978-981-10-3701-6_29 · Cited by 1
Management of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., Sgalla, G., & Richeldi, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00004-5 · Cited by 1
Management of Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Alharbi, A. R. (2024) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_98_23 · Cited by 1
Progress in the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Schwartz, R. S., & Glassberg, M. K. (2016) · touchREVIEWS in Respiratory & Pulmonary Diseases · doi:10.17925/usrpd.2016.01.01.22 · Cited by 1
Self-citationStudies on TGF-β family signalling in the diseased lung tissue
Leppäranta, O. (2012) · Helda - University of Helsinki Institutional Repository
Neue Empfehlungen bei idiopathischer Lungenfibrose
Markart, P., & Gesierich, W. (2015) · Pneumo News · doi:10.1007/s15033-015-0214-8
Symptom management: dyspnoea and cough
Wuyts, W. A. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006215
Raghu, G., Rochwerg, B. N., Zhang, Y., Cuello‐García, C. A., Azuma, A., Behr, J., Brożek, J., Collard, H. R., Cunningham, W., Homma, S. A., et al. (2017) · Advances in respiratory medicine · doi:10.5603/arm.50373
“Do drugiego, mniejszego badania włączono 29 pacjentów z chorobą łagodną do umiarkowanej (średnie DLCO 42% wartości przewidywanej) do grup otrzymujących sildenafil (20 mg 3 razy dziennie) lub placebo przez 6 miesięcy [46].”
BackgroundTreatment of Pulmonary Hypertension in Interstitial Lung Disease
King, C. S., & Nathan, S. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-49918-5_4
Does Sildenafil Improve Physical Function in Patients With Idiopathic Pulmonary Fibrosis
Mellinger, T. R. (2014) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
Blandinières, A. (2018) · theses.fr (ABES) · doi:10.70675/9178d6fcz7e4ez48deza1dcz0840f8c96b22
Lung Transplantation for Interstitial Lung Disease
Malouf, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-90933-2_12
Morphological and functional studies in a sheep model of pulmonary fibrosis
Dewage, V., & Nimanthi, S. (2020) · Minerva Access (University of Melbourne)
Idiopathic Pulmonary Fibrosis Clinical Trials: Evolving Concepts
Martínez, F. J. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_20 · Cited by 1
Diagnostic and Therapeutic Challenges for Patients with Pulmonary Hypertension due to Lung Diseases
Ribeiro, D. S., Godinas, L., & Delcroix, M. (2022) · Barcelona Respiratory Network · doi:10.23866/brnrev:2022-m0069
Mahmoud, M. (2024) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2024.353095
Nursing Challenges in Managing Pulmonary Hypertension
et al., A. B. O. A. (2023) · Letters in High Energy Physics
Metadata
- Authors
- Jackson, R. M., Glassberg, M. K., Ramos, C. F., Bejarano, P. A., Butrous, G., & Gómez-Marín, O.
- Affiliations
- University of Miami (US)
- Miami VA Healthcare System (US)
- University of Kent (GB)
- Corresponding author
- Jackson, Robert M.
- Venue
- Lung
- Published
- 2009-12-12
- Volume
- 188
- Issue
- 2
- Pages
- 115-123
- ISSN
- 0341-2040 (ISSN-L)
- 1432-1750
- OpenAlex
- W2029732141
- Cited by
- 92
- References
- 18
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 8 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 10 · 2015: 4 · 2014: 7 · 2013: 5 · 2012: 5
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Lung (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer UK
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, sildenafil, exercise tolerance, 6-minute walk test, dyspnea, Borg scale, lung function, phosphodiesterase-5 inhibitors
- MeSH terms
- Sildenafil Citrate, Aged, Aged, 80 and over, Double-Blind Method, Dyspnea, Exercise Test, Female, Humans, Male, Middle Aged, Phosphodiesterase Inhibitors, Pilot Projects, Piperazines, Pulmonary Diffusing Capacity, Purines, Sulfones, Time Factors, Vasodilator Agents, Vital Capacity, Treatment Outcome, Exercise Tolerance, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.